3A) and the same deletion was found in the mother (not shown). The exact details of the deletion are described elsewhere.2 The other mutation in the boy was identified by direct sequencing of the amplified fragments after PCR. A novel single base substitution C to T in exon 13 was found, resulting in the substitution of an arginine for cysteine in the epidermal growth factor homology region ( fig 3B) . Familial defective apolipoprotein B was excluded as a reason for the raised cholesterol concentrations in both the boy and his mother. The apolipoprotein E genotype was E4/3.
An immunoblot of the LDL receptor from lymphoblastoid cells from the boy and his mother ( fig 3C) showed an accumulation of a protein of approximately 100 kilodaltons (kd) in both individuals. There was also a normal sized protein in the cells from both the mother and her son, although the amount was reduced in the latter. Further analysis was not possible as no more cells were available.
Discussion
The good lipid lowering response to dietary advice and drug treatment in the boy raised the question as to whether the patient was homozygous for mutations in the LDL receptor gene or a severely affected heterozygote. In this case the DNA analysis enabled us to show that the patient was a compound heterozygote for familial hypercholesterolaemia.
Immunoblot analysis on lymphoblastoid cells from the boy and his mother, who also carried the large deletion, showed an accumulation of a protein of approximately 100 kd protein. It is likely that this protein accumulated within the cell because the transmembrane portion of the protein was deleted by the truncation but sequences that retain the protein within the cell were not. This mutation therefore resembles the Lebanese mutation which causes a premature stop codon in amino acid 660 in exon 14, and which has been shown to result in the accumulation of a truncated protein in the Golgi compartment,6 which has no residual receptor activity. detected at low levels in the lymphoblastoid cells of the patient ( fig 3C) . As further functional studies were not undertaken it is not known if there was delayed processing of the receptor protein from the precursor to the mature form during passage to the cell surface. The additional cysteine replacing an arginine might have such an effect but there was no evidence for accumulation of a normal sized precursor protein in the cells from the boy. It is also not known whether either of the mutated proteins retained any binding ability. In the light of the good response to treatment seen in this patient it is conceivable that the R612C mutation has some residual activity and a true homozygote for that mutation would respond even better than the compound heterozygote described here. Likewise, it may be predicted that a heterozygote for this mutation will have lower plasma cholesterol concentration as seems to be the case in heterozygous familial hypercholesterolaemia patients with mutations with some residual receptor activity. 4 There are a growing number of reports of phenotypically homozygous patients who have shown an unexpectedly good response to treatment.' This is usually related to the level of residual LDL receptor activity,8 but there is also a recent report of a receptor negative homozygote with familial hypercholesterolaemia who responded well to simvastatin treatment with a fall in plasma cholesterol concentrations of approximately 40%, which was stable over a two year period.9 There is, therefore, still much to be learned about the response to treatment of patients with homozygous familial hypercholesterolaemia.
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